Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 11-20 of 65
Breast Cancer
The STOP-HER2 Study
The STOP-HER2 Study Summary: HER2 positive (HER2+) breast cancers account for 20-25% of breast cancers and are associated with higher rates of recurrence and brain metastases. However, in the past two decades, HER2 targeting therapies have drastically improved patient outcomes and most patients treated with stage I-III HER2+ breast cancer are cured. For patients with […]
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Colorectal Cancer
SX-682 in combination with Nivolumab for ctDNA positive colorectal cancer
SX-682 in combination with Nivolumab for ctDNA positive colorectal cancer Summary: STOPTRAFFIC-1 is an ongoing phase I/II study assessing the experimental drug, SX-682, in patients with refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer. In collaboration with the NCI/SPORE program, Gateway will support the proposed “Arm B” of the study. This arm will assess colorectal […]
Benny Johnson, DO
MD Anderson Cancer Center
Solid Tumors
Responder-derived FMT and anti-PD-1 in PD-1 refractory melanoma and NSCLC
Responder-derived FMT and anti-PD-1 in PD-1 refractory melanoma and NSCLC Summary: Cancer cells evolve and develop protective mechanisms to hide themselves from cancer killing T-cells. Immune checkpoint inhibitors (ICI), block these protective mechanisms by targeting PD-1/PD-L1 (or CTLA-4), unhiding cancer cells so that they can be killed by T-cells. While ICIs have become the standard […]
Diwakar Davar, MD, MSc
University of Pittsburgh
Breast Cancer
Phase 1 trial of CD40 agonist, Flt3L, and chemotherapy in breast cancer
Phase 1 trial of CD40 agonist, Flt3L, and chemotherapy in breast cancer Summary: Triple negative breast cancer (TNBC) is associated with more aggressive disease compared to other subtypes of breast cancer, with a median survival of less than 18 months for a patient diagnosed with metastatic disease. Despite the success of immune checkpoint inhibitors in […]
Sangeetha Reddy, MD, MSCI
University of Texas Southwestern Medical Center
Blood Cancer
Ivosidenib in IDH1-mutated Clonal Cytopenia of Undetermined Significance
Ivosidenib in IDH1-mutated Clonal Cytopenia of Undetermined Significance Summary: Individuals with cytopenia (low blood cell counts) and clonal hematopoiesis (hee-MA-toh-poy-EE-sis), but do not meet the criteria for a hematologic malignancy have an entity called clonal cytopenias of undetermined significance (CCUS). These patients have an 82% chance of developing a hematologic malignancy in 5-years, 95% in […]
Kelly Bolton, MD, PhD
Washington University
Breast Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with expansion cohort in PD-L1 negative TNBC
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with expansion cohort in PD-L1 negative TNBC Summary: Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and it is highly aggressive, accounting for a disproportionate amount of metastatic […]
Yuan Yuan, MD, PhD
Cedars-Sinai Medical Center
Prostate Cancer
Clinical Trial of Androgen Deprivation Therapy and Copanlisib in High-Risk Prostate Cancer Patients with PTEN Loss Prior to Radical Prostatectomy
Clinical Trial of Androgen Deprivation Therapy and Copanlisib in High-Risk Prostate Cancer Patients with PTEN Loss Prior to Radical Prostatectomy Summary: Prostate cancer is the most common cancer in men and is the second leading cause of cancer death in men. It is characterized by dependence on the androgen receptor and activation of PI3K signaling […]
Dana Rathkopf, MD
Memorial Sloan Kettering Cancer Center
Brain Cancer
Mycophenolate Mofetil Combined With Standard of Care Chemoradiation in Newly Diagnosed Glioblastoma
Mycophenolate Mofetil Combined With Standard of Care Chemoradiation in Newly Diagnosed Glioblastoma Summary: Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Despite initial aggressive treatment with surgery followed by radiation therapy and chemotherapy, most patients relapse within one year, develop treatment resistance, and less than 10% live longer than five after […]
Yoshie Umemura, MD
University of Michigan
Brain Cancer
Evaluation of next-gen CAR-T cells targeting EGFRvIII and EGFR for GBM
Evaluation of next-gen CAR-T cells targeting EGFRvIII and EGFR for GBM Summary: Glioblastoma (GBM) is a deadly brain cancer with limited treatment options. Standard of care treatment is surgery followed by radiation and treatment with temozolomide, a chemotherapy. Standard of care has not changed in 15 years and despite treatment, most patients relapse in eight […]
Marcela Maus, MD, PhD
Massachusetts General Hospital Cancer Center
Head/Neck Cancer
HYHOPE: Phase I study of de-intensified hypofractionated radiation therapy for human papilloma virus-associated oropharynx cancer
HYHOPE: Phase I study of de-intensified hypofractionated radiation therapy for human papilloma virus-associated oropharynx cancer Summary: The incidence of Human Papilloma Virus-associated oropharyngeal squamous cell carcinoma is increasing in the United States accounting for 70-80% of newly diagnosed oropharyngeal cancers. Standard of care radiation therapy using conventional methods for oropharyngeal squamous cell carcinoma takes seven […]
Dominic Moon, MD
University of Texas Southwestern Medical Center
